Vemurafenib, an RAF inhibitor being used for metastic melanoma needs to be carefully monitored in patients as it appears to trigger off leukemia. Tough battle, trying to figure out what drugs work for which cancer. It is recommended that adjuvant treatment with RAF only be offered in the context of a clinical trial.
One side effect from Vemurafenib are cutaneous skin conditions. This has occurred in approximately 1/4 of all patients/clients while being administered with this drug.
(N.Engl.J.Med. 2012;367:1694-703 [doi:10.1056/NEJMoa1210093]).